Cambrex

Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized with 2023 CDMO Leadership Awards in the categories of Quality, Service, Expertise, and Compatibility. Additionally, Cambrex was selected as a “Champion” in the Service category. This marks the ninth consecutive year Cambrex has been acknowledged with an award.

Cambrex is an innovative life sciences company with a refreshingly human approach to the way we do business. Our pharmaceutical products, technologies and expertise accelerate your small molecule therapeutics into the market.

Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has completed its acquisition of Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.

Active ingredients, Dynamic people - From laboratory scale to commercial supply, enjoy working with the experts at Cambrex on your API.

Cambrex recently celebrated the 40th anniversary of its founding in 1981. Following forty years of growth and transformation into a leading global contract development and manufacturing organization (CDMO), Cambrex continues its commitment to leadership in pharmaceutical drug substance manufacturing with over $100 million of investments in progress across its global manufacturing network.

Drug formulations, Expertly finished - From pre-formulation registration batches and clinical supply to commercial manufacturing and packaging, Cambrex delivers your complex dosage forms with expertise.

Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing biopharmaceutical testing services business.

Analytical solutions, Quality assured - Trust our analytical development and testing experts to rapidly advance your molecule for the greatest chance of success.

Cambrex announced today the completion of a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Charles City, Iowa facility. The startup of the new manufacturing space is the culmination of a two-year project, originally announced in 2020, to increase the capacity of Cambrex’s flagship API facility by 30%. The expansion positions Cambrex with the largest and most advanced API facility in the United States and ensures the long-term capacity to support Cambrex’s existing customer base and future growth supported by robust market demand.

API Product List

Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced the acquisition of Q1 Scientific – a leading provider of environmentally-controlled cGMP stability storage services for the pharmaceutical, medical device and life science industries, strategically located in Waterford, Ireland.

Small molecules 2.0: the bigger picture” provides more than 80 pages of a selection of thought leadership articles our experts have contributed to which have been featured in global trade publications

Cambrex has completed an expansion of biopharmaceutical analysis capabilities at its Durham, North Carolina site, the contract development and manufacturing organisation said Tuesday.

With over 40 years’ experience and a growing team of over 2,100 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.

The transaction will enhance Cambrex's ability to service its global customer base and broaden its capabilities to provide additional world-class services.

Dr. Daniel Kirschner, Sr. Director, Analytical Development at Cambrex discusses abuse deterrent drug product formulations - quantifying the drug, excipient & degradants in abuse liability studies

The CDMO's shareholders will receive $60.00 per share in cash.

Dr. Darryl LeBlanc, Principal Scientist at Cambrex discusses impurity isolation & structural characterization

The expanded laboratory space will allow the installation of additional instruments and reactors for larger scale crystallization studies and solid form screening capabilities.

Brett Loungo, Environmental Monitoring Advisor at Cambrex discusses a risk-based approach to environmental monitoring

The process technology laboratories will include new capabilities in the scaling up of potent molecules requiring containment.

Investment will improve production cycle time and provide greater flexibility to customers.

New laboratory has installed a flow chemistry system to allow for continuous manufacturing development.

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

The $1 million investment will assist in getting new products to commercial launch faster.

Acquisition adds early-stage API and finished dosage form development & testing services to its global contract development & manufacturing network.

The investment increases the overall capacity and capabilities of the facility, and its flexibility.

Center will also focus on the development of new technologies, innovative chemistry and engineering solutions.

Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

Acquisition of Halo Pharma adds competencies including developing and manufacturing products for pediatric indications.

Company to increase the number of generic APIs in the company's development pipeline.

Money to be spent on augmenting capability and capacity for process development and scale up, handling of potent substances, crystallization studies and solid phase characterization.

Site's reactor capacity is increased by 30%.

The aboratory’s primary function is to broaden analytical support for customer projects being developed and manufactured at the High Point site.